Table 1.
Pulmonary function of patients with stable end-stage lung diseases
| Before the COVID–19 pandemic |
During the COVID–19 pandemic |
|||||
|---|---|---|---|---|---|---|
| COPD (n = 20) | ILD (n = 7) | others (n = 4) | COPD (n = 20) | ILD (n = 7) | others (n = 4) | |
| FVC, L mean (SD) | 1.87 (0.69) | 2.87 (1.69) | 1.58 (0.44) | 2.01 (0.72) | 2.89 (1.69) | 1.70 (0.28) |
| FEV1, L mean (SD) | 0.76 (0.27) | 2.32 (1.01) | 0.8 (0.16) | 0.77 (0.27) | 2.33 (1.01) | 0.80 (0.14) |
| FEV1/FVC, % mean (SD) | 41.88 (13.90) | 86.14 (9.79) | 51.14 (10.79) | 39.42 (1.62) | 85.16 (10.54) | 46.20 (3.89) |
| TLC, L mean (SD) | 7.30 (2.19) | 4.18 (2.01) | 5.54 (1.71) | 7.36 (2.19) | 4.32 (2.03) | 5.50 (1.59) |
| RV, L mean (SD) | 5.35 (1.89) | 1.30 (0.42) | 3.92 (1.54) | 5.28 (1.82) | 1.40 (0.50) | 3.73 (1.51) |
| R, kPa × s/L mean (SD) | 1.17 (0.64) | 0.24 (0.15) | 1.43 (0.49) | 1.13 (0.66) | 0.22 (0.11) | 1.47 (0.50) |
| Oxygen, L/min median (IQR) | 0.5 (0–2) | 2 (0–2) | 0.5 (0–1.75) | 1 (0–2) | 2 (0–2) | 1.5 (1–2.75) |
| pO2, mm Hg median (IQR) | 66.0 (62.5–71.0) | 71.0 (61–74) | 63.0 (57.2–66.5) | 76.0 (65.0–94.0) | 73.0 (66.0–103.0) | 90.0 (76.75–100.25) |
| pCO2, mm Hg median (IQR) | 43.5 (38.3–49.8) | 36.0 (35.0–42.0) | 43.0 (38. to 56.3) | 44.0 (39.3–52.0) | 36.0 (34.0–43.0) | 42.5 (36.8–47.5) |
| pH median (IQR) | 7.42 (7.40–7.44) | 7.43 (7.42–7.46) | 7.41 (7.38–7.47) | 7.42 (7.37–7.44) | 7.42 (7.41–7.44) | 7.41 (7.39–7.44) |
| HCO3–, mmol/L median (IQR) | 28.0 (26.0–32.0) | 25.0 (26.0–28.0) | 30.0 (25.3–34.0) | 28.5 (25.3–32.8) | 25.0 (24.0–27.0) | 25.5 (24.5–30.5) |
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second of expiration; FVC, forced vital capacity; HCO3–, bicarbonate; ILD, interstitial lung disease; pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen; R, resistance; RV, residual volume; TLC, total lung capacity; IQR, interquartile range.